Johnson & Johnson Opens Innovation Center in London

The company will pursue medical device, drug and packaging developments at the London facility.

Johnson & Johnson today announced the opening of the Johnson & Johnson Innovation centre in London, one of four regional hubs being established this year in the world's leading innovation hotspots.  A part of Johnson & Johnson Innovation, the goal of the London innovation centre is to accelerate the best early stage science in the world and advance the development of new healthcare solutions.   

Your rating: None Average: 5 (1 vote)

Bristol-Myers Squibb Funds Cancer Treatment Collaboration Grants

The company has donated a total of $175,000 to the American Cancer Society and Princeton HealthCare System to support cancer treatment and patient care.

Bristol-Myers Squibb has awarded grants totaling $175,000 to the American Cancer Society Eastern Division and Princeton HealthCare System (PHCS) to support comprehensive navigation services for patients with cancer both independently and as part of a collaborative effort among several hospitals in central New Jersey.

Your rating: None Average: 5 (1 vote)

Takeda Pharmaceuticals, Scripps Research Institute Expand Collaboration

The partnership is intended to identify potential new drugs and compounds for various diseases.

The Scripps Research Institute (TSRI) and the Takeda Pharmaceutical Company have announced plans to expand their recent research collaboration to search for new drug targets for a variety of diseases.

The new agreement extends an initial collaboration launched in 2010 between scientists on the Florida campus of TSRI and Envoy Therapeutics that led to several breakthroughs in identifying potential new compounds for neurological and psychiatric diseases. Envoy was acquired by Takeda Pharmaceuticals last November.

No votes yet

GVK Biosciences, Onconova Therapeutics to Partner on Cancer Drug Development

The pharmaceutical companies have formed a joint development partnership to advance new drugs for oncology patients.

GVK BIO, Asia’s leading Contract Research and Development organization and Onconova Therapeutics, a U.S. based biopharmaceutical company primarily focused on discovery and development of novel small molecules for Oncology, today announced that they have entered into a novel joint partnership to develop new drugs for Cancer.

No votes yet

Sanofi US Announces Honors Cross-disease Registry Idea

Pharmaceutical packaging firms, patients, medical staff and others could benefit from the registry, designed to foster collaboration in medical research.

Sanofi US announced today that Registries for All Diseases has been selected as the winner of the Collaborate Activate Innovation Challenge.

No votes yet

Janssen Research and Development Submits New Diabetes Treatment

The new drug application submitted to the FDA is a fixed-dose combination therapy for patients with Type 2 diabetes.

Janssen Research & Development, LLC  today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for a fixed-dose therapy combining canagliflozin and immediate release metformin to treat patients with type 2 diabetes.

No votes yet

Pfizer: Experimental Breast Cancer Treatment Shows Promise

The pharma firm reports that the treatment has show effectiveness in slowing the progression of advanced breast cancer.

Pfizer Inc. said Wednesday that an experimental breast cancer drug it is developing was more effective than an older therapy at slowing the progression of advanced breast cancer.

Your rating: None Average: 5 (1 vote)

Geron to Halt Brain-cancer Drug Development

The pharma firm reports it will trim its brain-cancer development efforts and staff to focus on other research.

Geron Corp. said it has stopped developing its treatment for brain cancers, and will cut its work force and replace its chief financial officer.

The pharmaceutical company said it plans to reduce its work force by 40% to 64 full-time positions. It expects to lower its annual cash operating expenses from about $65 million in 2012 to about $33 million in 2013--which includes nonrecurring costs of about $3 million associated with the restructuring and about $3 million for the discontinuation of clinical trials.

No votes yet

Report: Feds, Big Pharma Likely to Reduce Research Funding

Two Johns Hopkins faculty members predict drug developers may need to innovate to find other funding.

In a commentary to be published in the Dec. 12 issue of The Journal of the American Medical Association, two Johns Hopkins faculty members predict an ever-diminishing role for government and drug company funding of basic biomedical research and suggest scientists look to 'innovative' kinds of private investment for future resources.

Current negotiations in Washington over sequestration and the so-called 'fiscal cliff' provide an opportunity to fundamentally rethink the funding of biomedical research, they say.

No votes yet

Researchers to Collaborate on Treatments for Brain-disorder Patients

A group of companies at the recent CNS Summit agreed to work together toward accelerated development of novel treatments.

An exciting new era of “pre-competitive collaboration” in the development of treatments for patients suffering from brain disorders began when leading enterprises and institutions involved in CNS (central nervous system) clinical trials agreed to collaborate together towards the common goal of developing novel treatments for patients, in an area of medicine with high unmet need.
The agreement to rethink how companies interact and to streamline and accelerate CNS drug development was formed at the CNS Summit 2012, which took place November 15
No votes yet
Syndicate content